Taken together, we, therefore, conclude that acute hyperactivation of the PI3K/AKT pathway by introducing constitutively active AKT1 in CLL is detrimental for the cells in vitro and in vivo. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.